Diamyd Medical AB Class B DMYD_B

The Board of Directors of Diamyd Medical Aktiebolag ("Diamyd Medical" or the "Company") has resolved on a directed issue of 17,226,500 new Class B shares at a subscription price of SEK 13.54 per share, through which the Company receives approximately SEK 233 million before transaction costs (the "Share Issue"), and two directed issuances of an aggregate of 46,649,362 warrants (the "Warrant Issuances", and together with the Share Issue, the "Directed Issuances"), to certain U.S. sector specialist

The clinical database has been finalized for the pre-specified interim efficacy analysis in Diamyd Medical's ongoing pivotal Phase 3 trial (DIAGNODE-3) evaluating retogatein (rhGAD65) in individuals with Stage 3 type 1 diabetes. The outcome of interim analysis readout is expected by the end of March 2026.

Diamyd Medical today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent covering the intralymphatic administration of retogatein (rhGAD65) with alum for the prevention and treatment of type 1 diabetes.

As European markets navigate renewed trade and geopolitical uncertainties, with the STOXX Europe 600 Index recently ending lower, investors are keenly observing growth opportunities within the region. In this context, companies with high insider ownership often attract attention for their potential alignment of interests between management and shareholders, making them compelling considerations in a fluctuating market environment.

Diamyd Medical has reached alignment with the U.S. Food and Drug Administration (FDA) to accelerate the primary efficacy readout in its ongoing pivotal, registrational Phase 3 DIAGNODE-3 trial in type 1 diabetes from 24 to 15 months, per FDA guidance, enabling the full primary efficacy readout of the trial to occur nine months earlier than previously planned and communicated. The previously announced interim efficacy readout, involving approximately 170 participants with 15-month data, remains o